Amneal reports positive interim results for CREXONT in Parkinson's study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
June 5, 2026 8:00 AM EDTPhase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groupsSubstantial increases in daily Good On time, reductions in Off time, and meaningful improvements in motor function were observed after switching to CREXONT®Patients switching to CREXONT® from RYTARY® gained 3.03 hours of additional daily Good On time and nearly doubled the duration of continuous Good On intervals, enabling longer, uninterrupted periods of symptom control
BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals,... More
